Intellia Therapeutics, Inc. is planning to further beef up its pipeline on the back of data for two of its in vivo CRISPR/Cas9 candidates, saying that the results provide further validation for its programs overall, in addition to setting the two candidates up as potentially competitive in their respective indications.
On 16 September, Intellia presented interim results from the Phase I/II study of NTLA-2002 in hereditary angioedema (HAE) at the 2022 Bradykinin Symposium in Berlin
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?